Press release
Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast 2034". This comprehensive report provides an in-depth understanding of Primary Sclerosing Cholangitis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Discover Key Insights into the Primary Sclerosing Cholangitis Market with DelveInsight's In-Depth Report @ Primary Sclerosing Cholangitis Market Size [https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market?utm_source=abnews&utm_medium=pressrelease&utm_campaign=akpr]
Key Takeaways from the Primary Sclerosing Cholangitis Market
*
The market size for Primary Sclerosing Cholangitis in the leading markets is expected to grow USD 80 million by 2034.
*
The United States accounted for the highest Primary Sclerosing Cholangitis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
*
The US recorded the highest diagnosed Primary Sclerosing Cholangitis prevalence in 2023, with approximately 31 thousand cases, and is expected to grow further.
*
Among European countries, Germany had the highest prevalence (~5 thousand cases), followed by the UK, while Spain reported the lowest prevalence (~0.1 thousand cases).
*
Japan accounted for around 3 thousand diagnosed prevalent cases in 2023, representing nearly 5% of the total 7MM burden.
*
In the US, males accounted for the majority of diagnosed cases (~21 thousand) compared to females (~10 thousand) in 2023.
*
In Japan, 62% of diagnosed cases were asymptomatic, while 38% were symptomatic in 2023.
*
Inflammatory Bowel Disease (IBD) remains the leading comorbidity, with approximately 23 thousand associated cases in the US in 2023, a figure expected to increase over the forecast period.
*
Leading Primary Sclerosing Cholangitis companies developing emerging therapies, such as Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others, are developing new therapy for Primary Sclerosing Cholangitis that can be available in the Primary Sclerosing Cholangitis market in the coming years.
*
The promising Primary Sclerosing Cholangitis therapies in clinical trials include HTD 1801, PLN-74809 (bexotegrast), and others.
Keen to know more about the market? Request our sample page @ Primary Sclerosing Cholangitis Market Report [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnews&utm_medium=pressrelease&utm_campaign=akpr]
Key Factors Driving the Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis Market Drivers
*
Rising diagnosed prevalence of Primary Sclerosing Cholangitis across major markets.
*
Growing awareness and improvements in early disease diagnosis.
*
Strong pipeline development with emerging therapies such as bexotegrast and HTD1801.
*
Increased R&D investments and clinical trial activity by leading pharmaceutical companies.
Primary Sclerosing Cholangitis Market Landscape
*
Primary Sclerosing Cholangitis treatment primarily focuses on symptom management and slowing disease progression through ursodeoxycholic acid, endoscopic interventions, immunosuppressants, antibiotics, and antipruritic therapies. Liver transplantation remains the only curative option for advanced disease. With current treatments offering limited long-term benefits, emerging therapies such as HTD1801 hold promise for addressing significant unmet medical needs.
Primary Sclerosing Cholangitis Competitive Landscape
*
HTD 1801: HighTide Biopharma
HTD1801 is a first-in-class oral therapeutic composed of two active components, berberine and ursodeoxycholic acid, combined as a novel ionic salt. The drug functions as a lipid modulator and has demonstrated the ability to significantly reduce liver fat accumulation. HTD1801 has completed a Phase II clinical trial in Primary Sclerosing Cholangitis (PSC) and continues to be evaluated in Phase II studies for additional chronic diseases. It has been granted both Orphan Drug Designation (ODD) and Fast Track Designation (FTD). In June 2021, HighTide Therapeutics presented topline results from its PSC study of HTD1801 at the International Liver Congress 2021.
*
PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.
PLN-74809 (Bexotegrast) is an oral dual-selective v6/v1 integrin inhibitor being developed for Primary Sclerosing Cholangitis (PSC). By blocking integrin-mediated activation of TGF-, a key driver of fibrosis, the therapy aims to slow or prevent scar tissue formation in affected bile ducts. In July 2022, Pliant Therapeutics received FDA Fast Track Designation (FTD) for PLN-74809 in PSC.
Recent Developments in the Primary Sclerosing Cholangitis Market
*
In May 2026, Ipsen announced result of A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis
What is Primary Sclerosing Cholangitis?
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts inside and outside the liver. Over time, the bile ducts become narrowed or blocked, leading to bile buildup, liver damage, and potentially liver failure. PSC is often associated with inflammatory bowel diseases, particularly ulcerative colitis. Common symptoms include fatigue, itching, abdominal discomfort, and jaundice, although some patients remain asymptomatic for years. Currently, there is no cure for PSC, and treatment focuses on managing symptoms, preventing complications, and, in advanced cases, liver transplantation.
Download the report to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology Trends @ Primary Sclerosing Cholangitis Prevalence [https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market?utm_source=abnews&utm_medium=pressrelease&utm_campaign=akpr]
Primary Sclerosing Cholangitis Epidemiology Segmentation
The Primary Sclerosing Cholangitis epidemiology section provides insights into the historical and current Primary Sclerosing Cholangitis patient pool and forecasted trends for the leading markets. The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
*
Diagnosed PSC Prevalence Across the 7MM
*
Gender-Based PSC Prevalence in the 7MM
*
Symptom-Specific PSC Patient Distribution in the 7MM
*
Comorbidity-Associated PSC Cases in the 7MM
Download the sample page to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology Trends @ Primary Sclerosing Cholangitis Prevalence [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnews&utm_medium=pressrelease&utm_campaign=akpr]
Scope of the Primary Sclerosing Cholangitis Market Report
*
Coverage- 7MM
*
Study Period- 2020-2034
*
Forecast Period- 2024-2034
*
Primary Sclerosing Cholangitis companies: Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
*
Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and emerging therapies
*
Primary Sclerosing Cholangitis Market Dynamics: Key Market Forecast Assumptions of Emerging Primary Sclerosing Cholangitis Drugs and Market Outlook
*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
*
Unmet Needs, KOL's views, Analyst's views, Primary Sclerosing Cholangitis Market Access and Reimbursement
Table of Contents
1. Primary Sclerosing Cholangitis Market Key Insights
2. Primary Sclerosing Cholangitis Market Report Introduction
3. Primary Sclerosing Cholangitis Market Overview at a Glance
4. Primary Sclerosing Cholangitis Market Executive Summary
5. Disease Background and Overview
6. Primary Sclerosing Cholangitis Treatment and Management
7. Primary Sclerosing Cholangitis Epidemiology and Patient Population
8. Patient Journey
9. Primary Sclerosing Cholangitis Marketed Drugs
10. Primary Sclerosing Cholangitis Emerging Drugs
11. Seven Major Primary Sclerosing Cholangitis Market Analysis
12. Primary Sclerosing Cholangitis Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-market-is-projected-to-boom-by-2034-owing-to-the-launch-of-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market
Country: United States
Website: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight here
News-ID: 4536897 • Views: …
More Releases from ABNewswire
Tendinopathy Market is Expected to Witness Significant Growth by 2036 Owing to t …
The market dynamics for Tendinopathy are witnessing considerable growth driven by increasing prevalence of tendon injuries, rising participation in sports and physical activities, growing aging population, and advancements in regenerative medicine approaches. Additionally, the launch of emerging therapies such as TenoMiR (CWT-001) and other biologic therapies will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Tendinopathy Market Insights, Epidemiology, and Market…
Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancem …
The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies. The anticipated launch of innovative therapies such as Retatrutide, Survodutide, CagriSema, VK2735, and Amycretin is expected to further accelerate market growth across the 7MM during the forecast period.
DelveInsight, a leading business consulting and market research…
Hereditary Angioedema (HAE) Market is Expected to Witness Significant Growth by …
The market dynamics for Hereditary Angioedema (HAE) are witnessing considerable growth driven by increasing awareness and diagnosis rates, advancements in prophylactic and on-demand therapies, and the emergence of novel gene-editing and RNA-targeted therapies. Additionally, the launch of emerging therapies such as ADX-324 (ADARx Pharmaceuticals), Lonvoguran ziclumeran/NTLA-2002 (Intellia Therapeutics), Navenibart (Astria Therapeutics), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report,…
Adrenoleukodystrophy Market is Expected to Witness Significant Growth by 2036 Ow …
The market dynamics for Adrenoleukodystrophy (ALD) are witnessing steady growth driven by the increasing adoption of newborn screening programs, growing awareness regarding rare neurodegenerative disorders, advancements in gene therapy approaches, and rising focus on disease-modifying treatments. Additionally, the launch of emerging therapies such as Leriglitazone (MIN-102) (Minoryx Therapeutics and Neuraxpharm), VK0214 (Viking Therapeutics), PXL065 (Poxel), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release…
More Releases for Primary
Premier Primary Care Medicine Recognized as a Top Primary Care Doctor in Smyrna, …
Premier Primary Care Medicine has been recognized as one of the Top Primary Care Doctors in Smyrna, GA, a distinction that underscores the practice's dedication to delivering high-quality, patient-focused healthcare to the local community. This recognition affirms the practice's strong reputation for clinical expertise, compassionate service, and commitment to improving long-term health outcomes for patients across Smyrna and surrounding areas.
SMYRNA, GA - March 3, 2026 - Premier Primary Care [https://www.premierpcmed.com/]…
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
